Imagine if doctors could tell exactly who needs chemotherapy and who doesn't just by looking at a digital photo of a tumor. Right now, many people get harsh treatments they don't actually need because the current tests aren't precise enough. This tool uses AI to scan those images and accurately predict if a patient will truly benefit from the medicine.
Up to 90% of colorectal cancer patients receiving adjuvant chemotherapy may not benefit from it, leading to severe side effects and unnecessary healthcare spending.
Deep learning algorithms applied to cancer tissue whole slide images (WSI) to stratify patient risk.
If you are a hospital lab dealing with the high cost and risk of over-treating cancer patients — this project developed AI software that identifies low-risk patients in minutes. This can prevent up to 250,000 patients from receiving unnecessary chemotherapy.
If you are an insurer dealing with the high cost of cancer care and side-effect hospitalizations — this project developed a biomarker that could save 4 billion EUR globally every year by reducing unnecessary treatments.
If you are a software provider dealing with the need for more clinical utility in digital pathology — this project developed a deep learning algorithm for whole slide images that provides a hazard ratio >10 for risk stratification.
Based on available project data, the tool can identify patients who do not need adjuvant chemotherapy, potentially saving 4 billion EUR globally every year.
Yes, the test can be run in local labs using existing digital pathology equipment and does not consume any tissue.
Based on available project data, the technology is developed by DoMore Diagnostics AS, but specific licensing terms are not provided.
The biomarker provides risk stratification (low, intermediate, or high) with a hazard ratio >10.
The project period is from 2024-06-01 to 2026-05-31, focusing on broadening clinical validations to become the gold standard.
The project is led by a single partner, DoMore Diagnostics AS, a Norwegian SME. This 100% industry-led structure suggests a strong focus on commercialization and rapid market entry rather than academic exploration.
Contact DoMore Diagnostics AS in Norway
Contact us to explore licensing or partnership opportunities with DoMore Dx.
